Several previous studies in ovarian cancer have demonstrated that increased cGMP/PKG signaling decreases activation of both the MAPK and AKT pathways, and that this corresponds with decreased proliferation and increased apoptosis [55–57]. This evidence concerns the gene PRKG1 and ovarian carcinoma.